Oramed Pharmaceuticals Inc Stock Price, News & Analysis

Oramed Pharmaceuticals (Nasdaq: ORMP) will have CEO Nadav Kidron present an overview at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 11:30 AM ET. The company is focused on oral drug delivery systems, aiming to revolutionize diabetes treatment with its lead candidate, ORMD-0801, potentially the first oral insulin capsule. Oramed has completed multiple Phase II trials and is also developing ORMD-0901, an oral GLP-1 analog.

Oramed Pharmaceuticals announced its participation in the AAPS 2020 PharmSci 360 conference, presenting research on its oral insulin candidate, ORMD-0801, for Type 2 diabetes. The presentation, led by Dr. Miriam Kidron, focuses on the glycemic effects of bedtime oral insulin in uncontrolled diabetes patients. Oramed aims to innovate diabetes treatment through its proprietary Protein Oral Delivery (POD™) technology, with ORMD-0801 potentially being the first oral insulin capsule. The company has completed multiple Phase II clinical trials under FDA regulations.

Oramed Pharmaceuticals (NASDAQ: ORMP) announced a webinar titled "The Journey of Oral Insulin: Oramed Story," featuring CEO Nadav Kidron and Premas Biotech's Dr. Prabuddha Kundu on October 28, 2020, at 9:00 am ET. The session highlights the advancements in oral insulin delivery, focusing on Oramed's oral insulin capsule, ORMD-0801, which is entering pivotal Phase 3 trials in the U.S. Established in 2006, Oramed aims to revolutionize diabetes treatment with its oral drug delivery technology.

Oramed Pharmaceuticals has submitted protocols for pivotal Phase 3 studies of its oral insulin candidate, ORMD-0801, to the FDA following guidance from the agency. The two studies aim to evaluate the safety and efficacy of ORMD-0801 in approximately 1,125 patients with type 2 diabetes. The U.S. study, ORA-D-013-1, plans to recruit 675 patients across 75 sites, while ORA-D-013-2 will involve 450 patients across 61 sites. Patient enrollment is expected this quarter, with efficacy data anticipated after a 6-month treatment period.

Oramed Pharmaceuticals (Nasdaq: ORMP) announced its participation in the EASD Annual Meeting, taking place virtually from September 21-25, 2020. Dr. Roy Eldor will present on September 22 at 3:45 p.m. CEST, discussing the glycaemic effects of oral insulin (ORMD-0801) in type 2 diabetes patients. Additionally, Dr. Miriam Kidron will showcase a poster on September 24 at 12:00 p.m. CEST, detailing oral insulin's impact on liver fat in T2DM patients with NASH. Oramed focuses on transforming diabetes treatment with its oral insulin capsule technology.

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced that CEO Nadav Kidron will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference, scheduled for September 14-16, 2020. Kidron's presentation will take place on September 15 at 1:30 PM Eastern. Oramed specializes in oral drug delivery solutions, aiming to transform diabetes treatment with its lead candidate, ORMD-0801, the first oral insulin capsule. The company has completed multiple Phase II clinical trials and is also developing an oral GLP-1 analog capsule, ORMD-0901.

Oramed Pharmaceuticals announced positive feedback from the FDA during its End of Phase 2 meeting regarding its oral insulin, ORMD-0801. The FDA's feedback paves the way for Oramed to initiate two concurrent Phase 3 clinical trials after protocol review. Successful trials could lead to a Biologics License Application (BLA), which would grant 12 years of marketing exclusivity for ORMD-0801. The company aims to address unmet needs in diabetes treatment with this innovative oral insulin product.

Oramed Pharmaceuticals announced positive preliminary results from a pilot study on its oral insulin candidate, ORMD-0801, aimed at treating type 2 diabetes patients with non-alcoholic steatohepatitis (NASH). The study showed that ORMD-0801 was safe and well tolerated, with a mean reduction of 6.9% in liver fat content after 12 weeks. Additionally, significant decreases in gamma-glutamyltransferase and fasting insulin levels were observed. These findings were presented at the 80th American Diabetes Association Scientific Sessions, signaling potential for further research and clinical trials.